---
title: "GLP-1 developer Kailera, proteomics firm Alamar file for U.S. IPOs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280879865.md"
description: "Kailera Therapeutics and Alamar Biosciences have filed for U.S. IPOs. Kailera, focused on weight loss drugs, plans to list on Nasdaq under \"KLRA\" with its lead candidate, ribupatide, in Phase 3 trials. The company reported a $149M net loss in 2025. Alamar, specializing in proteomics, aims to list under \"ALMR\" and reported $74.2M revenue in 2025, with a narrowed net loss of $29.8M. Both companies are seeking to raise capital through their IPOs."
datetime: "2026-03-28T13:57:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280879865.md)
  - [en](https://longbridge.com/en/news/280879865.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280879865.md)
generator: "portal-rs"
---

# GLP-1 developer Kailera, proteomics firm Alamar file for U.S. IPOs


### Related Stocks

- [GRTX.US](https://longbridge.com/en/quote/GRTX.US.md)
- [NBSE.ESC.US](https://longbridge.com/en/quote/NBSE.ESC.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ALGS.US](https://longbridge.com/en/quote/ALGS.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [MBX.US](https://longbridge.com/en/quote/MBX.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [CYTOF.US](https://longbridge.com/en/quote/CYTOF.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [GRTXD.US](https://longbridge.com/en/quote/GRTXD.US.md)

## Related News & Research

- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md)
- [Analyst Maintains Buy on Microbix as China Antigen Sales Normalize and Revenue Growth Recovers](https://longbridge.com/en/news/296018935.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**